Affimed (NASDAQ:AFMD) Sees Significant Drop in Short Interest

Affimed (NASDAQ:AFMD) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 611,400 shares, a drop of 39.5% from the November 15th total of 1,010,000 shares. Currently, 4.7% of the company’s stock are sold short. Based on an average daily trading volume, of 180,400 shares, the short-interest ratio is currently 3.4 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Stifel Nicolaus reduced their price target on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. Finally, Wells Fargo & Company lowered their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Affimed presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares in the last quarter. Choreo LLC purchased a new stake in shares of Affimed during the second quarter valued at $54,000. Intellectus Partners LLC increased its holdings in shares of Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the period. Jane Street Group LLC acquired a new stake in shares of Affimed in the third quarter worth $44,000. Finally, Point72 Asset Management L.P. lifted its position in Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

Affimed Stock Performance

Shares of Affimed stock opened at $2.15 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The stock’s fifty day moving average price is $3.08 and its 200-day moving average price is $4.17. Affimed has a 12 month low of $2.02 and a 12 month high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.